Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vermylen J
J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):182-5.
Ketanserin (3 X 40 mg daily) was administered during 6 weeks in 14 patients with mild to moderate essential hypertension using a double-blind, placebo-controlled, crossover design. Ketanserin decreased (p less than 0.01) the recumbent blood pressure from 159/104 to 153/97 mm Hg and the recumbent heart rate from 75 to 72 beats/min. Platelet aggregation induced by 5-hydroxytryptamine (5-HT), whether or not amplified by threshold doses of collagen, was not inhibited; however, it was reduced in 10 normal volunteers after a single oral dose of 40 mg ketanserin. The results suggest that long-term treatment with ketanserin reduces blood pressure; whereas 5-HT receptor inhibition could not be demonstrated when assessed by platelet aggregation.
采用双盲、安慰剂对照、交叉设计，对14例轻至中度原发性高血压患者给予酮色林（每日3次，每次40毫克），疗程6周。酮色林使卧位血压从159/104毫米汞柱降至153/97毫米汞柱（p<0.01），卧位心率从75次/分钟降至72次/分钟。5-羟色胺（5-HT）诱导的血小板聚集，无论是否由阈剂量胶原增强，均未受到抑制；然而，10名正常志愿者单次口服40毫克酮色林后，血小板聚集减少。结果表明，酮色林长期治疗可降低血压；而通过血小板聚集评估时，未证实5-HT受体受到抑制。
